DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Antonia SJ, Lopez-Martin JA, Bendell J. et al.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial.
Lancet Oncol 2016;
17: 883-895
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.